Sleep disorders and inflammatory disease activity: Chicken or the egg?

American Journal of Gastroenterology

Volumn 110, Issue 4, 2015, Pages 484-488

  Parekh, Parth J ^a   Oldfield Iv, Edward C ^a   Challapallisri, Vaishnavi ^a   Ware, J Catsby ^a   Johnson, David A ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL STUDY; DISEASE SEVERITY; HUMAN; INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; RISK FACTOR; SLEEP DISORDER; SLEEP PATTERN; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; CROHN DISEASE; DISEASE MODEL; GENETICS; INFLAMMATORY BOWEL DISEASES; METABOLISM; NEOPLASMS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SLEEP; SLEEP DEPRIVATION; ULCERATIVE COLITIS;

ANIMALS; C-REACTIVE PROTEIN; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MELATONIN; NEOPLASMS; QUALITY OF LIFE; RECURRENCE; SIGNAL TRANSDUCTION; SLEEP; SLEEP DEPRIVATION; SLEEP DISORDERS; TOLL-LIKE RECEPTOR 4;

EID: 84927765741     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.247     Document Type: Article

References (62)

1. Forsyth CB, Banan A, Farhadi A. et al. Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther 2007; 321: 84-97.
2. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on meta-bolic and endocrine function. Lancet 1999; 354: 1435-9.
3. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in infl ammatory bowel disease. Aliment Pharmacol Ther. 2007; 25: 247-55.
4. Birrenbach T, B ö cker U. Infl ammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Infl amm Bowel Dis 2004; 10: 848-59.
5. Ananthakrishnan AN, Long MD, Martin CF. et al. Sleep disturbance and risk of active disease in patients with Crohn ' s disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013; 11: 965-71.
6. Gómez-gonzález B, Domínguez-salazar E, Hurtado-alvarado G. et al. Role of sleep in the regulation of the immune system and the pituitary hormones. Ann N Y Acad Sci 2012; 1261: 97-106.
7. Nojkov B, Rubenstein J, Chey WD. et al the impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol 2010; 105: 842-7.
8. Kinnucan JA, Rubin DT, Ali T. Sleep and infl ammatory bowel disease: exploring the relationship between sleep disturbances and infl ammation. Gastroenterol Hepatol (NY) 2013; 9: 718-27.
9. Hakim F, Wang Y, Zhang SX. et al. Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. Cancer Res 2014; 74: 1329-37.
10. Richardson GS the human circadian system in normal and disordered sleep. J Clin Psychiatry 2005; 66 (Suppl 9): 3-9.
11. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139-50.
12. Musiek ES, Fitzgerald GA. Molecular clocks in pharmacology. Handb Exp Pharmacol 2013; 217: 243-60.
13. Green CB, Takahashi JS, Bass J the meter of metabolism. Cell 2008; 134: 728-42.
14. Institute of Medicine (US) Committee on Sleep Medicine and Research Institute of Medicine (US) Committee on Sleep Medicine and Research-Colten HR, Altevogt BM eds. In. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. National Academies Press: Washington, DC, 2006.
15. Lange T, Dimitrov S, Born J. Eff ects of sleep and circadian rhythm on the human immune system. Ann. N Y Acad Sci 2010; 1193: 48-59.
16. Ranjbaran Z, Keefer L, Farhadi A. et al. Impact of sleep disturbances in infl ammatory bowel disease. J Gastroenterol Hepatol 2007; 22: 1748-53.
17. Tan DX, Manchester LC, Hardeland R. et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res 2003; 34: 75-8.
18. Reiter RJ the melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654-64.
19. Malpaux B, Migaud M, Tricoire H. et al. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J Biol Rhythms 2001; 16: 336-47.
20. Kunz D, Mahlberg R, Muller C. et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab 2004; 89: 128-34.
21. Petrie K, Dawson AG, Th ompson L. et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 1993; 33: 526-30.
22. Hughes RJ, Badia P. Sleep-promoting and hypothermic eff ects of daytime melatonin administration in humans. Sleep 1997; 20: 124-31.
23. Bubenik GA, Blask DE, Brown GM. et al. Prospects of the clinical utilization of melatonin. Biol Signals Recept 1998; 7: 195-219.
24. Messener M, Huether G, Lorf T. et al. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-51.
25. Bubenik GA. Th irty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59: S33-51.
26. Carrillo-Vico A, Reiter RJ, Lardone PJ. et al the modulatory roleof melatonin on immune responsiveness. Curr Opin Invest Drugs 2006; 7: 423-31.
27. Dong WG, Mei Q, Yu JP. et al. Eff ects of melatonin on the expression of iNOS and COX -2 in rat model of colitis. World J Gastroenterol 2003; 9: 1307-11.
28. Mei Q, Xu JM, Xiang L. et al. Change on nitric oxide in experimental colitis and its inhibition by melatonin invivo and invitro. Postgrad Med J 2005; 81: 667-72.
29. Li JH, Yu JP, Yu HG. et al. Melatonin reduces infl ammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Infl amm 2005; 4: 185-93.
30. Marquez EK, Sanchez-Fidalgo S, Calvo JR. et al. Acutely administered melatonin is benefi cial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res 2006; 40: 48-55.
31. Mei Q, Yu JP, Xu JM. et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-6.
32. Necefl i A, Tulumoglu B, Gris M. et al. Protective effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-45.
33. Nosal' ova V, Zeman M, Cerna S. et al. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 2007; 42: 364-70.
34. Esposito E, Mazzon E, Riccardi L. et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin in experimental colitis. J Pineal Res 2008; 45: 166-73.
35. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995; 19: 31-9.
36. Mazzon E, Esposito E, Crisafulli C. et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-73.
37. Malhotra S, Bhasin D, Shafi q N. et al. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opin Pharmacother 2004; 5: 329-34.
38. Jan JE,O'Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996; 21: 193-9.
39. Messener M, Huether G, Lorf T. et al. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-51.
40. Chen Chun-Qiu, Fichna Jakub, Bashashati Mohammad. et al. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 2011; 17: 3888-98.
41. Preuss F, Tang Y, Laposky AD. et al. Adverse eff ects of chronic circadian desynchronization in animals in a ' challenging ' environment. Am J Physiol Regul Integr Comp Physiol 2008; 295: R2034-40.
42. Tang Y, Preuss F, Turek FW. et al. Sleep deprivation worsens infl ammation and delays recovery in a mouse model of colitis. Sleep Med 2009; 10: 597-603.
43. Deng WG, Tang ST, Tseng HP. et al. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006; 108: 518-24.
44. Sasaki M, Jordan P, Joh T. et al. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol 2002; 2: 9.
45. Boznanska P, Wichan P, Stêpien A. et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lekarski 2007; 22: 369-72.
46. Chojnacki C, Poplawski T, Blasiak J. et al. Does melatonin homeostasis play a role in continuous epigastric pain syndrome?. Int J Mol Sci 2013; 14: 12550-62.
47. Arendt J, Bojkowski C, Franey C. et al. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-73.
48. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998; 24: 58-61.
49. Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and infl ammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci 2003; 48: 743-9.
50. Keefer L, Stepanski E, Ranjbaran Z. et al. An initial report of sleep disturbance in inactive infl ammatory bowel. J Clin Sleep Med 2006; 2: 409-16.
51. Ali T, Madhoun MF, Orr WC. et al. Assessment of the relationship between quality of sleep and disease activity in infl ammatory bowel disease patients. Infl amm Bowel Dis 2013; 19: 2440-3.
52. Graff La, Clara I, Walker JR. et al. Changes in fatigue over 2 years are associated with activity of infl ammatory bowel disease and psychological factors. Clin Gastroenterol Hepatol 2013; 11: 1140-6.
53. LaFlamme B. Poor sleep and tumor progression. Nat Genet 2014; 46: 219.
54. Jess T, Horvath-Puho E, Fallingborg J. et al. Cancer risk in infl ammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013; 108: 1869-76.
55. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-45.
56. Jess T, Simonsen J, Jorgensen KT. et al. Decreasing risk of colorectal cancer in patients with infl ammatory bowel disease over 30 years. Gastroenterol 2012; 143: 375-81.
57. Bonny O, Firsov D. Circadian regulation of renal function and potential role in hypertension. Curr Opin Nephrol Hypertens 2013; 22: 439-44.
58. Monk TH, Buysse DJ. Exposure to shift work as a risk factor for diabetes. J Biol Rhythms 2013; 28: 356-9.
59. Grundy A, Richardson H, Burstyn I. et al. Increased risk of breast cancer associated with long-term shift work in Canada. Occup Environ Med 2013; 70: 831-8.
60. Schernhammer ES, Feskanich D, Liang G. et al. Rotating night-shift work and lung cancer risk among female nurses in the United States. Am J Epidemiol 2013; 178: 1434-41.
61. Flynn-evans EE, Mucci L, Stevens RG. et al. Shift work and prostate-specifi c antigen in the National Health and Nutrition Examination Survey. J Natl Cancer Inst 2013; 105: 1292-7.
62. Mann S. Melatonin for ulcerative colitis?. Am J Gastroenterol 2003; 98: 232-3.